PolyPid (NASDAQ:PYPD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of PolyPid (NASDAQ:PYPD) from a sell rating to a hold rating in a research report report published on Sunday.

Several other equities research analysts also recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of PolyPid in a research report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $13.00 target price on shares of PolyPid in a research note on Wednesday, August 13th. Roth Capital decreased their target price on PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Finally, Craig Hallum reiterated a “buy” rating and set a $13.00 price target (down previously from $15.00) on shares of PolyPid in a report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.40.

PolyPid Trading Up 0.3%

Shares of PYPD opened at $3.64 on Friday. The business’s 50-day moving average price is $3.50 and its 200 day moving average price is $3.37. The stock has a market capitalization of $57.88 million, a P/E ratio of -1.22 and a beta of 1.53. PolyPid has a 1-year low of $2.30 and a 1-year high of $3.93.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.17. On average, research analysts predict that PolyPid will post -1.79 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PYPD. AIGH Capital Management LLC increased its position in PolyPid by 27.0% in the 2nd quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock worth $4,215,000 after purchasing an additional 253,727 shares during the last quarter. Lumbard & Kellner LLC bought a new stake in shares of PolyPid in the 2nd quarter valued at approximately $135,000. Finally, BNP Paribas Financial Markets increased its holdings in PolyPid by 56.1% in the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after buying an additional 3,500 shares during the last quarter. Hedge funds and other institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.